Grail, the company developing a blood test for cancer, saw its shares jump on Monday after the FDA published documents ahead of an advisory committee meeting. The documents concern Galleri, the company's multi-cancer detection test, and set the stage for a public review of the evidence.
The advisory committee vote is expected to carry weight for Grail, patients, and regulators alike. A favorable outcome could bolster the test's path forward, while a negative one might slow its progress. The exact contents of the FDA documents were not detailed in the report.
For now, the market reaction signals optimism, but the committee's decision remains the key unknown. The meeting will likely shape how regulators approach similar blood-based cancer screening tools in the future.